Rhumbline Advisers Kinnate Biopharma Inc. Transaction History

Rhumbline Advisers

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$1.38 - $3.31 $2,300 - $5,517	-1,667 Reduced 36.24%	2,933 $4,000
Q2 2023 Aug 08, 2023	SELL	$2.33 - $6.84 $111,311 - $326,767	-47,773 Reduced 91.22%	4,600 $13,000
Q1 2023 May 11, 2023	BUY	$3.46 - $7.98 $21,894 - $50,497	6,328 Added 13.74%	52,373 $327,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $1,430 - $3,315	272 Added 0.59%	46,045 $281,000
Q3 2022 Nov 10, 2022	BUY	$9.86 - $15.76 $27,765 - $44,380	2,816 Added 6.56%	45,773 $547,000
Q2 2022 Aug 11, 2022	BUY	$7.43 - $13.0 $80,823 - $141,414	10,878 Added 33.91%	42,957 $542,000
Q1 2022 May 12, 2022	BUY	$7.73 - $17.99 $13,983 - $32,543	1,809 Added 5.98%	32,079 $361,000
Q4 2021 Feb 10, 2022	BUY	$16.5 - $25.48 $4,917 - $7,593	298 Added 0.99%	30,270 $536,000
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $258,547 - $361,037	14,517 Added 93.93%	29,972 $690,000
Q2 2021 Aug 05, 2021	BUY	$22.19 - $31.55 $83,390 - $118,564	3,758 Added 32.13%	15,455 $360,000
Q1 2021 May 06, 2021	BUY	$26.99 - $40.0 $315,702 - $467,880	11,697 New	11,697 $364,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.